DOI: 10.1128/CVI.00089-15
Article Figures & Data
Tables
- TABLE 1
Rationale for vaccine development for nontypeable Haemophilus influenzae
Infection Population to vaccinate What vaccine will accomplish Otitis media All children beginning at 2 mo of age Prevention of: Acute otitis media Recurrent otitis media Chronic otitis media Otitis media with effusion related to bacterial biofilm formation Chronic suppurative otitis media Reductions in: Excess antibiotic use Health care costs Exacerbation of COPD Adults with COPD Prevention of: Acute exacerbations of COPD Chronic airway colonization Reductions in: Excess antibiotic use Health care costs - TABLE 2
Haemophilus influenzae vaccine antigens under study
Antigen Molecular mass (kDa) Function Reference(s) Haemophilus adhesin protein (Hap) ∼155 Adhesin 71–73 HMW1, HMW2 120–125 Adhesins 74–76 H. influenzae adhesin (Hia) ∼115 Adhesin 77, 78 D15 protein ∼80 Predicted nucleotidyltransferase 79, 80 HtrA ∼46 Heat shock protein 81 P2 porin 36–42 Porin protein 65, 66, 82 Lipoprotein D ∼42 Glycerophosphodiester phosphodiesterase 45, 56, 83 P5 fimbrin 27–35 Adhesin, OMP A-like protein 51, 84–86 P4 protein ∼30 Acid phosphatase 87–89 Protein F ∼30 Adhesin, ABC transporter 90–92 OMP 26 ∼26 Skp family of translocation proteins 85, 93–95 P6 protein ∼16 Peptidoglycan-associated lipoprotein 96–102 Protein E ∼16 Adhesin, binds IgD 103–106 PilA (type IV pilus) ∼14 Adhesin, transformation 51, 107–109 Detoxified lipooligosaccharide 3–5 Endotoxin 110–113